The emergence of the novel ß-coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic of coronavirus disease 2019 (COVID-19). Clinical studies have documented that potentially severe neurological symptoms are associated with SARS-CoV-2 infection, thereby suggesting direct CNS penetration by the virus. Prior studies have demonstrated that the destructive neurological effects of rabies virus (RABV) infections are mediated by CNS transport of the virus tightly bound to the nicotinic acetylcholine receptor (nAChR). By comparison, it has been hypothesized that a similar mechanism exists to explain the multiple neurological effects of SARS-CoV-2 via binding to peripheral nAChRs followed by orthograde or retrograde transport into the CNS. Genetic engineering of the RABV has been employed to generate novel vaccines consisting of non-replicating RABV particles expressing chimeric capsid proteins containing human immunodeficiency virus 1 (HIV-1), Middle East respiratory syndrome (MERS-CoV), Ebolavirus, and hepatitis C virus (HCV) sequences. Accordingly, we present a critical discussion that integrates lessons learned from prior RABV research and vaccine development into a working model of a SARS-CoV-2 vaccine that selectively targets and neutralizes CNS penetration of a tightly bound viral nAChR complex.
- MeSH
- Betacoronavirus chemistry immunology MeSH
- Spike Glycoprotein, Coronavirus chemistry genetics immunology MeSH
- Coronavirus Infections immunology metabolism prevention & control virology MeSH
- Humans MeSH
- Receptors, Nicotinic metabolism MeSH
- Pandemics MeSH
- Protein Domains MeSH
- Virus Replication * MeSH
- Pneumonia, Viral immunology virology MeSH
- Viral Vaccines chemistry immunology metabolism MeSH
- Rabies virus genetics physiology MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
